Search

You searched for "transurethral"

200 results found

Prostate Cancer Diagnosis – PSA, Biopsy and Beyond

1 September 2015 | | URO - Basic Science Research, URO - Urologic Oncology
The danger of many of the texts which deal with this rapidly changing field is that by the time the texts are published they are out of date. This book however remains fresh, in part because it acknowledges that there...

Fluoroquinolone resistant rectal colonisation predicts risk of infectious complications after TRPB

1 March 2015 | | URO - Basic Science Research
Transrectal prostate biopsy (TRPB) has been associated with increased risk of infection between 3.6-5% and sepsis rates of 0.3-3.1% mainly due to fluoroquinolone resistance (FQR). At present, FQ antibiotic prophylaxis is utilised commonly across North America and Europe but due...

Male infertility

1 May 2018 | | URO - Andrology
Definitions Infertility is the inability of a sexually active, non-contracepting couple to achieve spontaneous pregnancy in one year [1]. About 15% of couples do not achieve pregnancy within one year and seek medical treatment for infertility. Semen parameters are standardised...

The how, why and when of bladder washouts: a guide

23 November 2022 | | URO - Functional / Reconstructive Urology, URO - Infection
Bladder washouts are a treatment usually employed by the urology team, more often in an inpatient setting, and commonly indicated for haematuria with clot retention and catheter bypassing [1,2]. Bladder washout is a cornerstone of treatment in urology wards, yet...

Bladder carcinoma MRI

1 September 2018 | | URO - Urologic Oncology, URO - Uroradiology
Bladder malignancy is one of the commonest malignancies of the renal tract, accounting for approximately 6% of male malignancy and 2% of female malignancy. The incidence increases with patient age with 70% of patients being over the age of 65...

Nocturia – the Cinderella of lower urinary tract symptoms

1 March 2014 | | URO - Functional / Reconstructive Urology
Nocturia is defined as waking during the night (at least once) to urinate. The important part of the definition relates to the necessity of sleep to precede the episode (although whether sleep must follow the episode is less clear). The...

Non-urothelial bladder malignancies

3 May 2024 | | URO - Urologic Oncology
Case 1 An 80-year-old gentleman presented with a history of visible haematuria and recurrent urinary tract infections (UTIs). He has been performing intermittent self catheterisation (ISC) for detrusor underactivity for over 20 years. A flexible cystoscopy showed these appearances of...

The value of Urolink: an OOPE experience

1 May 2019 | | URO - Core Urology
I was fortunate enough to be able to take some time out of my training after ST5 to pursue an Out Of Programme Experience (OOPE) year. During the Urolink meeting at the British Association of Urological Surgeons (BAUS) 2017 conference...

Robotic Urology Fellowship at UCLH

1 May 2016 | | URO - Core Urology
In November 2014, approaching my final year of training (ST7) in the West of Scotland (WoS) and just recently armed with my FRCS (Urol), I was at a crossroad in my clinical career. I was keen to pursue a consultant...

Neuroendocrine bladder tumour

5 February 2025 | | URO - Urologic Oncology
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

A guide to local anaesthetic transperineal prostate biopsy

2 November 2023 | | URO - Urologic Oncology
In the UK, nearly 100,000 men undergo a prostate biopsy annually, a figure projected to double in the next decade [1]. In recent years, we have observed a paradigm shift in urological practice in numerous UK hospitals. The conventional transrectal,...

Fusion Bx 2.0 targeted prostate biopsy solution receives CE Mark

4 November 2019 | Research & Development
Focal Healthcare, an innovator of image-guided prostate cancer technology, has received CE Mark for its Fusion BxTM 2.0 prostate fusion biopsy solution.